TrialBlood2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Ian W Flinn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
189 papers cite itlatest 60 shown
this paperpooled ittrialcites it
TrialBlood2018
Ian W Flinn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.